Valencia, 2011
New concepts for drug development: Interfering with protein-protein interaction in cis-platinum resistant ovarian.The Thymidylate pathway – Maria Paola Costi, Italy
Molecular Analysis of Ovarian Cancer Disseminating Cells (OCDC)– Clues for Prognosis and Therapy Prediction? – Burkhard Brandt, Germany
Integrating histopathology and molecular markers: new opportunities for management – new challenges for clinical trials – David Huntsman, Canada
New insights of ovarian cancer etiology – Ivo Meinhold-Heerlein, Germany
Translational Research– Ovarian Cancer: Definition, Histopathology, Heterogeneity, Future Directions – John A. Green, UK
FDG PET as a predictor of response in gynaecological cancer clinical trials – Daniel O Slosman, France
New Biomarkers For (Early) Detection od Ovarian Cancer – Dietmar Pils, Dan Cacsire Castillo-Tong, Georg Heinze, Paul Speiser, OVCAD Consortium